Biomarine company Hofseth International AS has created a new division, Hofseth Biocare (Oslo, Norway), for the purpose of entering the global omega-3 market.
Biomarine company Hofseth International AS has created a new division, Hofseth Biocare (Oslo, Norway), for the purpose of entering the global omega-3 market. The company says that its omega-3 is superior compared to conventional fish oil ingredients because its patented processing yields fresher, purer, and sustainable ingredients.
“Conventional fish oil ingredients are commonly derived from biomass that is a degraded meal, which requires extensive filtration and processing, yielding oils that are heavily refined, with many of the active constituents thrown out,” stated Sjur Jenssen, CEO of Hofseth Biocare. “Our oil will definitely make a real difference and true point of differentiation, like no other omega-3 oil I’ve ever seen.”
The company says that its patented, enzyme-driven production processes marine biomass at low temperatures. It says this approach yields ingredients that are fresh, pure, and 100% sustainable, with no impact on wild salmon populations.
“We start with fresh salmon, and we extract virgin salmon oil within 24 hours,” Jenssen added. “The oil is very stable, and all of the natural constituents are preserved; thus, the oil even has a natural pink salmon color.”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.